OXLUMO has been shown to significantly reduce urinary oxalate, which drives the progression of PH1 Disease 1 MISSISSAUGA, ON , July 2, 2025 /CNW/ - Alnylam Canada ULC is pleased to announce that OXLUMO ® (lumasiran) is now funded across Canada through both public and private plans. OXLUMO is an RNA interference (RNAi) therapeutic administered via subcutaneous injection, indicated for the treatment of primary hyperoxaluria... Read More